EQS-News: Carl Zeiss Meditec with stable reve...

Margins and earnings fell sharply as revenue declined across key regions and businesses.

What the company is saying

Carl Zeiss Meditec AG presents a factual summary of its first nine months of fiscal 2025/26, highlighting a revenue decline to €1,553.7m and a drop in adjusted EBITA to €124.5m. The company frames its narrative around operational realities, explicitly noting the -2.9% revenue decrease and a significant margin contraction to 8.0%. Management emphasizes ongoing portfolio optimization, integration of ophthalmic surgery units, and evaluates manufacturing expansion, particularly mentioning India. Forward-looking guidance is provided, with full-year revenue expected at €2.15bn–€2.20bn and an adjusted EBITA margin between 8% and 10%, while also disclosing a projected €150m goodwill impairment in Ophthalmology. The tone remains neutral and measured, with no attempt to mask negative trends or overstate future prospects. Notable individuals named are Justus Felix Wehmer (CFO) and Sebastian Frericks (Head of Group Finance & Investor Relations), but their involvement is procedural rather than a signal of external validation.

What the data suggests

The reported numbers show a broad-based deterioration in financial performance. Revenue fell by €46.4m year-on-year to €1,553.7m, with adjusted EBITA dropping €52.5m to €124.5m and the margin contracting from 11.1% to 8.0%. Ophthalmology SBU revenue declined by -4.8% to €1,191.4m, while Microsurgery SBU grew by +3.8% to €362.3m, partially offsetting the group decline. Gross margin slipped from 52.7% to 51.0%, and the OpEx ratio rose to 45.6%, indicating cost pressures. Regional breakdowns reveal EMEA growth (+5.4%), but significant declines in APAC (-8.7%) and a modest drop in Americas (-2.6%). Earnings per share fell to €0.80 from €1.02, and adjusted EPS to €1.02 from €1.23. The recurring revenue share edged down to 50.9%. Disclosures are detailed for the income statement but lack cash flow, balance sheet, and absolute recurring revenue or order backlog figures, limiting full financial assessment.

Analysis

The announcement is factual and measured, with no evidence of narrative inflation or exaggerated tone. The majority of key claims are realised, backward-looking financial results, which show a deterioration in revenue, margins, and earnings per share. Forward-looking statements are limited to standard guidance for the remainder of the fiscal year and medium-term margin targets, but these are not presented in a promotional or aspirational manner. There is no attempt to reframe negative results positively, nor are there claims of imminent turnaround or outsized future benefits. The only significant forward-looking item is the expected goodwill impairment, which is itself a negative. No large capital outlay is paired with long-dated, uncertain returns. The gap between narrative and evidence is minimal; the data supports the company's statements.

Risk flags

• ●Profitability risk is elevated, as adjusted EBITA margin fell from 11.1% to 8.0% and gross margin declined by 1.7 percentage points, reflecting both revenue pressure and rising costs.
• ●Regional and business unit concentration risk is evident, with Ophthalmology SBU and APAC region both posting significant declines (-4.8% and -8.7% respectively), which are not fully offset by growth elsewhere.
• ●Disclosure risk remains, as the company omits absolute figures for recurring revenue and order backlog, and provides no cash flow or balance sheet data, preventing a comprehensive assessment of liquidity or leverage.
• ●Execution risk is present in the company's forward-looking statements about integrating business units, optimizing the manufacturing footprint, and achieving medium-term margin recovery, as no concrete evidence of operational turnaround is provided.
• ●Impairment risk is explicit, with a €150m goodwill write-down in Ophthalmology expected in Q4, signaling that prior acquisitions or investments have underperformed and may further impact reported earnings.

Bottom line

This interim update signals clear operational and financial deterioration, with revenue, margins, and earnings all down year-on-year. The company is transparent about negative trends and does not attempt to spin the results, but the absence of key disclosures—such as cash flow, balance sheet, and absolute recurring revenue—limits a full risk assessment. Forward-looking guidance for the year is modest and does not imply a near-term turnaround, while the expected €150m goodwill impairment highlights further downside to reported earnings. Without evidence of sequential improvement or new commercial wins, the narrative remains weak and the investment case unconvincing. The most important takeaway is that margin pressure and regional weakness are persistent, and management’s operational adjustments have yet to translate into measurable financial recovery.

Announcement summary

(LSE/AIM:0DHC) Carl Zeiss Meditec AG reported revenue of around €1,553.7m in the first nine months of fiscal year 2025/26, compared to €1,600.1m in the prior year, representing a decline of -2.9% (adjusted for currency effects: 0.0%). Adjusted EBITA amounted to €124.5m (prior year: €177.0m), with an adjusted EBITA margin of 8.0% (prior year: 11.1%). The Ophthalmology SBU saw revenue decline by -4.8% to €1,191.4m, while the Microsurgery SBU increased revenue by +3.8% to €362.3m. The EMEA region achieved revenue growth of +5.4% to €509.0m, Americas revenue was €397.0m (-2.6%), and APAC revenue declined by -8.7% to €647.8m. Gross margin stood at 51.0% (prior year: 52.7%), and earnings per share amounted to €0.80 (prior year: €1.02). The company expects fiscal year 2025/26 revenue to reach around €2.15bn to €2.20bn, with an adjusted EBITA margin between 8% and 10%, and projects an impairment of goodwill of around €150m in the Ophthalmology SBU in Q4 2025/26.

Disagree with this article?